These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36387034)

  • 1. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate.
    Lyons J; Hughes R; McCarthy K; Everage N; Kapadia S; Miller C; Singhal P; Smirnakis K
    Mult Scler J Exp Transl Clin; 2022; 8(4):20552173221132469. PubMed ID: 36387034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
    Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
    Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
    Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion.
    Garcia J; Hendel-Chavez H; De-Goer MG; L'Honneur AS; Dubessy AL; Taoufik Y; Stankoff B
    Mult Scler; 2021 Apr; 27(4):640-644. PubMed ID: 32686582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
    Longbrake EE; Naismith RT; Parks BJ; Wu GF; Cross AH
    Mult Scler J Exp Transl Clin; 2015; 1():. PubMed ID: 26550483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
    Wood CH; Robertson NP; Htet ZM; Tallantyre EC
    Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varicella-Zoster Reactivation in a Non-immunized Elderly Multiple Sclerosis Patient While on Delayed-Release Dimethyl Fumarate With Grade 2 Lymphopenia and Profoundly Low CD4+ and CD8+ Cell Counts: A Case Report.
    Daripa B; Lucchese S
    Cureus; 2022 Feb; 14(2):e22679. PubMed ID: 35386173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding spectrum of opportunistic infections associated with dimethyl fumarate.
    Kim T; Croteau D; Brinker A; Jones DE; Lee PR; Kortepeter CM
    Mult Scler; 2021 Jul; 27(8):1301-1305. PubMed ID: 33300850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions.
    Vola EA; Petracca M; Cocozza S; De Angelis M; Carotenuto A; Pontillo G; Morra VB; Tedeschi E; Lanzillo R
    BMC Neurol; 2021 Apr; 21(1):146. PubMed ID: 33820529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate.
    Sangurdekar D; Sun C; McLaughlin H; Ayling-Rouse K; Allaire NE; Penny MA; Bronson PG
    Front Genet; 2019; 10():1039. PubMed ID: 31749835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
    Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
    Prosperini L; Pontecorvo S
    Ther Clin Risk Manag; 2016; 12():339-50. PubMed ID: 27042079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.